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Abstract
Background: Uganda recently adopted artemether-lumefantrine (AL) as the recommended first-line treatment for
uncomplicated malaria. However, AL has several limitations, including a twice-daily dosing regimen, recommendation for
administration with fatty food, and a high risk of reinfection soon after therapy in high transmission areas.
Dihydroartemisinin-piperaquine (DP) is a new alternative artemisinin-based combination therapy that is dosed once daily
and has a long post-treatment prophylactic effect. We compared the efficacy and safety of AL with DP in Kanungu, an area
of moderate malaria transmission.
Methodology/Principal Findings: Patients aged 6 months to 10 years with uncomplicated falciparum malaria were
randomized to therapy and followed for 42 days. Genotyping was used to distinguish recrudescence from new infection. Of
414 patients enrolled, 408 completed follow-up. Compared to patients treated with artemether-lumefantrine, patients
treated with dihydroartemisinin-piperaquine had a significantly lower risk of recurrent parasitaemia (33.2% vs. 12.2%; risk
difference=20.9%, 95% CI 13.0–28.8%) but no statistically significant difference in the risk of treatment failure due to
recrudescence (5.8% vs. 2.0%; risk difference=3.8%, 95% CI 20.2–7.8%). Patients treated with dihydroartemisinin-
piperaquine also had a lower risk of developing gametocytaemia after therapy (4.2% vs. 10.6%, p=0.01). Both drugs were
safe and well tolerated.
Conclusions/Significance: DP is highly efficacious, and operationally preferable to AL because of a less intensive dosing
schedule and requirements. Dihydroartemisinin-piperaquine should be considered for a role in the antimalarial treatment
policy of Uganda.
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Introduction
With the emergence of widespread resistance to chloroquine
(CQ) and sulfadoxine-pyrimethamine (SP), most African countries
have adopted artemisinin-based combination therapy (ACT) as
first-line treatment for uncomplicated malaria. Although several
ACTs exist, currently only two have been widely adopted into
policy in Africa: artesunate-amodiaquine (AS/AQ) and arte-
mether-lumefantrine (AL), each of which is the recommended
therapy for uncomplicated malaria in over a dozen countries [1].
At the time when many countries needed to switch to ACTs, there
was limited data comparing ACT efficacy as was the case in
Uganda in 2004 when AL was chosen to replace the combination
of CQ+SP. Since then several studies in East Africa, including
Uganda, have shown AL to be highly efficacious and well-
tolerated[2,3,4,5,6]. AL demonstrated superior efficacy over AS/
AQ in all 4 studies that included this comparison[2,3,4,5].
However, AL has several limitations, including a twice-daily
dosing regimen, recommendation for administration with fatty
food, and a high risk of reinfection soon after therapy in high
transmission areas[2].
Dihydroartemisinin-piperaquine (DP) is a fixed-dose ACT
which has recently become available in Africa. This drug is
relatively inexpensive and has the advantages of once a day dosing
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studies of over 2,300 patients treated with DP in Asia, this drug
was found to be safe and well tolerated, with cure rates consistently
exceeding 95%[7].
There have been three published studies of DP in Africa. In all
of these studies DP was associated with excellent safety and
efficacy, as well as a lower risk of recurrent malaria compared to
AS/AQ [8] and AL[9,10]. One of these studies was done by our
group in an area of high transmission in Uganda[9], one in an
area of intense seasonal transmission in Burkina Faso[10], and one
at 3 sites in Rwanda where the levels of transmission intensity were
not specified[8]. Previous data from our group have shown that
the efficacy of antimalarial therapy may vary according to the level
of transmission intensity, likely due to differences in acquired
immunity and the risk of new infections following therapy[11].
In contrast to our previous study done in an area of high
transmission intensity, this trial was conducted in an area of
moderate transmission intensity in Uganda. We compare the
efficacy and safety of DP with the current first-line therapy, AL,
testing the hypothesis that the risk of recurrent parasitaemia would
differ between the two treatment arms. We also discuss the policy
implications of these findings in the context of a growing body of
evidence for the ACTs in Africa.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participants
The study was conducted at Kihihi Health Centre, Kanungu
District, Western Uganda. This district experiences perennial
mesoendemic malaria; the entomological inoculation rate was
measured at 7 infectious bites per person per year[12].
Consecutive patients presenting to the health center with
symptoms suggestive of malaria and a positive screening thick
blood smear were referred to study physicians for further
assessment. Patients were enrolled if they fulfilled the following
selection criteria: 1) age 6 months to 10 years; 2) weight $5 kg, 3)
history of fever in the last 24 hours or axillary temperature
$37.5uC; 4) no history of serious side effects to study medications;
5) no evidence of a concomitant febrile illness; 6) provision of
informed consent by a parent or guardian; 7) no danger signs or
evidence of severe malaria; and 8) P. falciparum mono-infection
with parasite density 2,000–200,000/ml of blood. Because
laboratory results were generally not available until the following
day, a patient could be excluded after randomization.
Ethics
The study protocol was approved by the Makerere University
Research and Ethics Committee, the Uganda National Council of
Science and Technology, and the University of California, San
Francisco Committee for Human Research. Parents or guardians
of all participating children provided written informed consent
before children could be enrolled into the study.
Interventions
A nurse administered study medications according to weight-
based guidelines for fractions of tablets. We administered all drugs
orally as follows: AL (Coartem, Novartis, 20 mg artemether/
120 mg lumefantrine tablets), administered as one (5–14 kg), two
(15–24 kg), three (25–34 kg), or four ($35 kg) tablets given twice
daily for 3 days; DP (Duocotecxin, Holley Pharm, 40 mg
dihydroartemisinin/320 mg piperaquine tablets), targeting a total
dose of 6.4 and 51.2 mg/kg of dihydroartemisinin and piper-
aquine, respectively, given in 3 equally divided daily doses to the
nearest J tablet (cut with a pill cutter). Participants in the DP
group also received placebo tablets administered in the evening
over 3 days to simulate the AL dosing schedule. Study medications
were administered with water, and patients were given a glass of
milk after each dose of study medication. All treatment was
directly observed at the study clinic. Participants were given the
option either to wait at the clinic for the evening dose (lunch was
provided) or to leave and return to the study clinic in the evening
(transport was provided). After each dose, children were observed
for 30 minutes, and the dose was re-administered if vomiting
occurred. All patients were provided with a 3-day supply of
acetaminophen for treatment of febrile symptoms. Children with
haemoglobin of less than 10 gm/dL were treated according to
Integrated Management of Childhood Illness guidelines with
ferrous sulfate for 14 days and antihelmintic treatment if
appropriate. Households of all patients were given two long-
lasting insecticide treated bednets (Permanet, Vestergaarad
Frandsen, Denmark) on the day of enrollment, with instructions
for one net to be used by the study patient.
Patients were asked to return for follow-up on days 1, 2, 3, 7, 14,
21, 28, 35 and 42, and any other day that they felt ill. Follow-up
evaluation consisted of a standardized history and physical
examination, including neurological assessment on all days of
follow up. We obtained blood by fingerprick for thick blood
smears and storage on filter paper on all follow-up days except day
1. Haemoglobin measurement was repeated on day 42 or the day
of recurrent symptomatic malaria. If patients did not return for
follow-up, they were visited at home.
Treatment failures received quinine (10 mg/kg orally three
times a day for 7 days). Patients with evidence of severe malaria or
danger signs (convulsions, lethargy, unable to drink or breast feed,
repeated vomiting, unable to stand/sit due to weakness) were
referred for treatment with parenteral quinine. Patients were
excluded during follow-up for use of antimalarial drugs outside of
the study, serious adverse events requiring a change in treatment,
withdrawal of informed consent, or loss of follow-up (not located
within 24 h Days 1–3 or 48 h Days 4–42).
Laboratory procedures
Initial screening blood smears were stained with 10% Giemsa
for 10 minutes. Thick and thin blood smears were stained with 2%
Giemsa for 30 minutes. Parasite densities were determined from
thick blood smears by counting the number of asexual parasites
per 200 white blood cells (WBCs), or per 500 if the count was less
than 10 parasites per 200 WBCs, assuming a WBC count of
8,000/ml. A smear was considered negative if no parasites were
seen after review of 100 high-power fields. We also assessed for the
presence of gametocytes from thick blood smears. Expert
microscopists reviewed thin blood smears for non-falciparum
infections using known defining characteristics to differentiate
between species [13].A second microscopist, who was unaware of
the results of the first reading, re-read all slides. A third
microscopist unaware of the first two readings resolved discrepant
readings. Haemoglobin measurements were made using a portable
spectrophotometer (HemoCue, A ¨ngelholm, Sweden).
Molecular genotyping techniques were used to distinguish
recrudescent from new infections for all patients with a late
clinical failure (LCF) or late parasitological failure (LPF) response.
Parasite DNA was isolated from filter paper blood samples
collected at enrollment and on the day of recurrent parasitaemia
using chelex extraction. Paired samples were genotyped in a
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A recrudescence was defined as the presence of at least one
matched allele at every locus; if at least one locus showed only
unmatched alleles, the outcome was classified as a new infection.
Objectives
The objective of the study was to compare the efficacy and
safety of DP with the current first-line therapy, AL, for treating
uncomplicated falciparum malaria in an area of moderate
transmission intensity in Uganda.
Outcomes
Treatment outcomes were classified according to 2006 WHO
guidelines as early treatment failure (defined as the presence of
danger signs, complicated malaria, or failure to adequately
respond to therapy on days 0–3), LCF (presence of danger signs,
complicated malaria, or fever and parasitaemia on days 4–42),
LPF (presence of asymptomatic parasitaemia on days 7–42) or
adequate clinical and parasitological response (absence of
parasitaemia throughout follow-up[15]. Secondary outcomes
included resolution of fever, parasite clearance, change in
haemoglobin level, presence of gametocytes during follow-up,
and the occurrence of adverse events.
At each follow-up visit study clinicians assessed patients for
adverse events and graded them according to scales from the
WHO and National Institutes of Health. Adverse events were
defined as untoward medical occurrences, following International
Conference on Harmonization guidelines, and serious adverse
events as experiences resulting in death, life-threatening experi-
ence, inpatient hospitalization, persistent or significant incapacity,
or medical or surgical intervention to prevent serious outcomes.
Sample size
We calculated sample size to test the hypothesis that the risk of
recurrent parasitaemia after 42 days would differ between the two
treatment groups. The risk of recurrent parasitaemia (unadjusted
by genotyping) after 42 days was estimated to be 50% after
treatment with AL based on previous data[2]. Using this estimate,
we calculated that 200 patients (allowing for 10% loss to follow-up)
would need to be enrolled in each treatment arm to detect a 15%
risk difference between the treatment groups with a two-sided type
I error of 0.05 and 80% power.
Randomization—Sequence generation
A randomization list was computer generated by an off-site
investigator. Sequentially numbered, sealed envelopes containing
the treatment group assignments were prepared from the
randomization list.
Randomization—Allocation concealment
Thestudynumberandassigned treatmentwereprinted ona card
and securely sealed in opaque envelopes. Sealed opaque envelopes
containing the study number and assigned treatment were secured
in a locked cabinet accessible only by the study nurse.
Randomization—Implementation
The nurse administered treatment by opening an envelope with
a matching treatment number sequentially assigned by the study
physician.
Blinding
Only the study nurse was aware of treatment assignments. All
other study personnel, including the study physicians and
laboratory personnel involved in assessing outcomes, were blinded
to the treatment assignments. Patients were not informed of their
treatment regimen, but the color and taste of the two study
medications were not the same (DP and placebo tablets were light
blue; AL tablets were light yellow).
Statistical methods
Data were entered and verified using Epi-Info version 6.04 and
analyzed using STATA version 8.0 (STATA Corporation, College
Station, TX, USA). Efficacy and safety data were evaluated using
a modified intention-to-treat analysis which included all patients
who fulfilled enrollment criteria. Patients who were randomized to
therapy but were not enrolled in the study due to laboratory results
not being available on day 0 were not included in the analysis.
Risks of treatment failure at 28 and 42 days of follow-up (adjusted
and unadjusted by genotyping) were estimated using the Kaplan-
Meier product limit formula. Data were censored for patients who
did not complete follow-up and for new infections when estimating
outcomes adjusted by genotyping. Patients with LCF or LPF due
to non-falciparum species were censored as non-failures at the
time they were classified as LCF or LPF. Comparisons of
treatment efficacy were made using risk differences (RD) with
exact 95% confidence intervals. Categorical variables were
compared using chi-squared or Fisher’s exact test and continuous
variables were compared using the independent samples t-test. All
reported p-values are two sided without adjustment for multiple
testing and were considered statistically significant if ,0.05.
Results
Participant flow
Of 463 patients screened, 2 were excluded during screening and
47 were excluded after treatment assignment, but before
enrollment (figure 1). Reasons for exclusion after treatment
assignment included non-falciparum malaria infection (n=36),
parasite density ,2,000/ml (n=4) or .200,000/ml (n=4), and
haemoglobin ,5.0 g/dL (n=3). Primary efficacy outcomes,
unadjusted and adjusted by genotyping, were available for 408
(98.6%) and 401 (96.9%) enrolled participants, respectively. All the
exclusions after enrolment were due to loss to follow-up.
Recruitment
Study participants were enrolled from August 2006 to April
2007.
Baseline data
Among patients with treatment outcomes, there were no
significant differences in baseline characteristics between the two
treatment groups (Table 1).
Numbers analyzed
Efficacy and safety data were evaluated using a modified
intention-to-treat analysis, which included all 414 patients who
fulfilled enrollment criteria (Table 2).
Outcomes and estimation
One participant treated with AL experienced early treatment
failure. The child had a febrile convulsion approximately eight
hours after administration of the first dose of treatment.
Intravenous quinine and supportive management were given
and the child recovered completely without any sequelae by day 3.
The characteristics of late clinical and parasitological failures are
presented in Table 2. Most presumed failures were due to new
ACT Therapy Options for Uganda
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risk of treatment failure unadjusted by genotyping was significantly
lower for participants treated with DP than for those treated with
AL after 28 (3.8% vs. 17.3%; RD=13.6%, 95% CI 7.7–19.4%)
and 42 days of follow up (12.2% vs. 33.2%; RD=20.9%, 95% CI
13.0–28.8%) (Table 3). Most episodes of recurrent parasitaemia
were seen $28 days after therapy in the AL group and $35 days
after therapy in the DP group (Figure 2). After correction by
genotyping, there was no statistically significant difference in the
risk of treatment failure after 28 days of follow up (0.9% vs. 3.2%;
RD=2.2%, 95% CI 20.6–5.1%); and although the risk of failure
tended to be lower in those treated with DP than for AL after 42
days of follow up, the difference did not reach statistical
Figure 1. Trial profile comparing antimalarial treatment regimens. AL=artemether-lumefantrine; DP=dihydroartemisinin-piperaquine.
doi:10.1371/journal.pone.0002390.g001
Table 1. Baseline characteristics of patients receiving either
dihydroartemisinin-piperaqine (DP) or artemether-
lumefantrine (AL)
Characteristic Treatment group
*
DP (n=215) AL (n=199)
Female (%) 114 (53%) 98 (49%)
Age in years, median (IQR) 2 (0.8–2) 2 (1.1–3.5)
Age less than 5 years (%) 180 (84%) 166 (83%)
Temperature uC, mean (SD) 38.1 (1.3) 38.2 (1.3)
Parasite density per mL, geometric
mean
33124 35211
Haemoglobin gm/dL, mean (SD) 9.9 (2.1) 9.9 (1.9)
Gametocytes present on day 0 (%) 12 (5.6%) 18 (9.1%)
Antimalarial use in previous 2
weeks (%)
71 (33%) 68 (34%)
doi:10.1371/journal.pone.0002390.t001
Table 2. WHO treatment outcomes after 42 days of follow-up
Treatment outcomes Treatment group
DP (n=215) AL (n=199)
Lost to follow-up (no treatment
outcome)
3 (1.4%) 3 (1.5%)
Early treatment failure (ETF) 0 1 (0.5%)
Late clinical failure (LCF) 9(4.2%) 23 (11.6%)
Due to new infection with
non-falciparum species
25
Due to new infection with
P. falciparum
61 4
Due to recrudescence 1 2
Genotyping unsuccessful 0 2
Late parasitological failure (LPF) 17 (7.9%) 41 (20.6%)
Due to new infection with
non-falciparum species
31 4
Due to new infection with
P. falciparum
10 16
Due to recrudescence 3 7
Genotyping unsuccessful 1 4
Adequate clinical and parasitological
response (ACPR)
186 (86.5%) 131 (65.8%)
doi:10.1371/journal.pone.0002390.t002
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(Table 3).
The proportion of patients with fever on Day 1 was significantly
lower in participants treated with DP (55% vs 68%, P=0.01), but
was similar over the second and third days of follow up in the two
treatment groups. Both treatments produced rapid clearance of
parasitaemia, with no parasites detected by day 3 (Table 4). The
appearance of gametocytes not present at enrollment was
significantly lower over the last 4 weeks of follow-up in participants
treated with DP (Table 4). This can be explained by differences in
the risk of recurrent parasitaemia as the risk of developing
gametocytes after therapy was significantly higher in patients with
recurrent parasitaemia compared to those without recurrent
parasitaemia in both the AL (34% vs. 1%, p,0.0001) and DP
(24% vs. 2%, p,0.0001) treatment arms.
Adverse events
No patients were withdrawn from the trial for vomiting that
would have required alternative treatment. Adverse events,
broadly defined as any untoward medical occurrences, occurred
commonly. Most adverse events were of mild or moderate severity
and consistent with symptoms due to malaria. The most
commonly reported adverse events in both treatment groups were
cough, coryza, abdominal pain, anorexia, weakness, diarrhea and
pruritus (Table 4). Adverse events were not significantly different
between the two treatment groups. A total of 7 serious adverse
events were reported in 7 patients. The distribution of the serious
adverse events was not significantly different in the two treatment
groups, except that an increased incidence of abdominal pain with
AL was of borderline significance. Serious adverse events included
convulsions (n=2), pyomyositis (n=2), vomiting (n=1), severe
Figure 2. Cumulative risk of recurrent parasitaemia, unadjusted by genotyping. AL=artemether-lumefantrine; DP=dihydroartemisinin-
piperaquine.
doi:10.1371/journal.pone.0002390.g002
Table 3. Estimates of comparative efficacy
Risk category DP (95% CI) AL (95% CI) RD (95% CI) p-value
28d risk of treatment failure unadjusted by genotyping
* 3.8% (1.9–7.4%) 17.3% (12.7–23.4%) 13.6% (7.7–19.4%) ,0.0001
28d risk of treatment failure adjusted by genotyping
{ 0.9% (0.2–3.7%) 3.2% (1.4–7.0%) 2.2% (20.6–5.1%) 0.12
42d risk of treatment failure unadjusted by genotyping
* 12.2% (8.5–17.5%) 33.2% (27.0–40.2%) 20.9% (13.0–28.8%) ,0.0001
42d risk of treatment failure adjusted by genotyping
{ 2.0% (0.7–5.1%) 5.8% (3.1–10.5%) 3.8% (20.2–7.8%) 0.06
*Any ETF, LCF or LPF
{Any ETF and LCF or LPF due to recrudescence
doi:10.1371/journal.pone.0002390.t003
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All serous adverse events were judged to be unrelated to study
medications. No deaths occurred in this study.
Discussion
Interpretation
In this study, we compared locally relevant antimalarial drug
combinations in a randomized trial of children with uncomplicat-
ed malaria, and followed up patients for 42 days. AL is currently
the first line treatment for malaria in Uganda
DP is a newer fixed combination regimen that is registered in
Uganda. Both regimens were highly efficacious in clearing initial
P. falciparum infections in children. However patients treated with
DP had a significantly reduced risk of treatment failure due to
recurrent parasitaemia and a lower risk of recurrent parasitaemia
due to recrudescence.
The risk of treatment failure unadjusted by genotyping, which
was significantly different between the two treatment arms, largely
reflects a difference in rates of reinfection, rather than recrudes-
cence. DP clearly offered a better post treatment prophylactic
effect following therapy compared to AL. The significant lower
risk of recurrent parasitaemia after treatment with DP is likely
explained by differences in pharmacokinetics of the non-
artemisinin partner drugs. Piperaquine, a bisquinoline, is estimat-
ed to have an elimination half-life of 2–3 weeks [16]; lumefantrine,
an aryl alcohol, has an estimated elimination half-life of 4–10 days
[17]. The performance observed for DP is consistent with results
from other recent studies in Africa [8,9,10] and prior studies in
Asia [18,19,20,21], suggesting that this combination may be highly
effective in areas with considerable resistance to other antimalarial
drugs. Other benefits offered by DP compared to AL include
simpler dosing, more consistent intestinal absorption, relatively
low cost, a lower risk of gametocytaemia after therapy and better
haemoglobin recovery [7]. Our study also offered a rigorous
comparison of the safety and tolerability of the two tested
regimens. Although, when defined as any untoward medical
occurrences, adverse events were common, drug-related adverse
events appeared to be uncommon and generally mild.
Five years after the call for deployment of artemisinin
combination therapy for treating malaria first gained momentum
[22], the strategic use of ACTs is now broadly accepted. A
remaining challenge, however, is the choice of ACT for first line
therapy in a particular country [23]. The WHO currently
recommends four ACTs for uncomplicated malaria; AS+me-
floquine, which is impractical for Africa due to high cost and
risk of toxicity; AS+sulfadoxine/pyrimethamine (SP), which
showed unacceptably poor efficacy in Uganda [24], probably
due to frequent parasite resistance to SP; AS+AQ, and AL. In
addition, DP is a newer ACT with excellent efficacy. In studies
in Uganda, AS+AQ was inferior to AL, with increased
recrudescence in Kampala [3] and increased recurrent (mostly
new) infections over 28 days in Tororo, a site with very high
transmission [2]. AS+AQ thus appears to be inferior to AL for
treating uncomplicated malaria in Uganda, probably due to
limited post-treatment prophylaxis with this regimen and
significant resistance of malaria parasites to AQ. However AL
has important limitations, including the need for twice-daily
dosing, irregular pharmacokinetics, and high rates of new
infections over 28–42 days in high transmission areas [2,9],
and consideration of DP as a superior therapy for uncomplicated
malaria is warranted.
Table 4. Secondary outcomes
Category Outcome Treatment group
DP (n=215) AL (n=199) p-value
Fever clearance
* Fever on day 1 117/213 (55%) 133/197 (68%) 0.01
Fever on day 2 44/213 (21%) 37/197 (19%) 0.71
Fever on day 3 22/213 (10%) 22/197 (11%) 0.87
Parasite clearance Parasitaemia on day 2 7/213 (3.3%) 5/197 (2.5%) 0.77
Parasitaemia on day 3 0 0 -
Appearance of gametocytes not present on day 0 Days 1–14. 4/201 (2.0%) 1/179 (0.6%) 0.38
Days 15–28 1/200 (0.5%) 7/178 (3.9%) 0.03
Days 29–42 4/194 (2.1%) 13/147 (8.8%) 0.005
Haemoglobin (Hb) recovery
{ Mean increase (SD) in Hb (g/dL) 1.75 (1.8) 1.66 (2.0) 0.63
Patients with adverse events of any severity Cough 164/213 (77%) 150/198 (76%) 0.77
Coryza 159/213 (75%) 150/198 (76%) 0.80
Abdominal pain 17/74 (23%) 24/63 (38%) 0.05
Anorexia 47/213 (22%) 49/198 (25%) 0.52
Vomiting 35/213 (16%) 35/198 (18%) 0.74
Weakness/malaise 28/213 (13%) 27/198 (14%) 0.88
Diarrhea 26/213 (12%) 23/198 (12%) 0.85
Pruritis 8/213 (4%) 3/198 (1.5%) 0.16
Patients with serious adverse events 5/215 (2.3%) 2/199 (1.0%) 0.45
*Subjective fever over previous 24 hours or temperature $37.5uC
{Change in Hb from day 0 to day 42 or day of clinical failure
doi:10.1371/journal.pone.0002390.t004
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This study was conducted in a moderate transmission area, but
the results are consistent with those from studies from high
transmission sites in Africa [8,9,10]. Therefore considered
together, the evidence adduced can be applied to other malaria
settings in Africa.
Overall evidence
Our results add to recent data comparing DP to other
artemisinin combination treatments of interest. In this study, DP
is clearly superior to AL at preventing new malaria infections; is at
least as safe as AL; and with simpler dosing requirements and
lower cost, it appears to be a preferable alternative.
This study adds data from a moderate transmission site to two
prior studies at high transmission sites in Africa [8,9,10] including
one very high transmission site in Uganda [9], all showing superior
efficacy for DP over AL, due to a lower risk of recurrent malaria
after therapy. This raises the question of what role DP should play
in Uganda’s antimalarial treatment policy. Although the question
of whether ACTs can be safely and effectively introduced into the
home based management of fever programme (HBMF) has not
been fully answered, and recognizing the challenges of changing
drug policy, it is possible that DP could be introduced into HBMF
instead of AL as planned. Additionally DP could replace AQ +AS
as the official first line alternative in Uganda, and possibly other
countries in Africa.
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